BioFocus and Astellas Pharma in target discovery deal

The collaboration will focus on discovering novel targets in the field of CNS disorders

BioFocus has signed a collaboration agreement with Tokyo-based Astellas Pharma focused on discovering novel targets in the field of CNS disorders.

Under the agreement, BioFocus will use its SilenceSelect target discovery platform to deliver validated targets to enhance the Astellas neurology pipeline and will receive research funding and success payments based on the progress of the collaboration.

As a service division of Galapagos, BioFocus looks to accelerate the gene-to-drug candidate discovery process. This is achieved through a comprehensive discovery platform, as well as diverse compound libraries, in vitro and cell-based screening, structural biology, medicinal chemistry, ADME/PK services.

‘We are delighted to support Astellas Pharma in its research,’ said Dr Chris Newton, SVP Galapagos Services and md of BioFocus. ‘Our target discovery offering allows clients to access a unique platform providing rapid identification of novel targets through a proven technology.’



Companies